Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. unveiled that they have signed a binding Letter of Intent for a strategic collaboration to bring GRAIL’s GalleriⓇ multi-cancer early detection (MCED) test to key Asian markets. SCT and SEC have also planned to invest USD 110 million into GRAIL, a healthcare company whose mission is to detect cancer early when it can be cured, at a price of USD 70.05 per share of common stock.
GRAIL and SCT will work as exclusive partners to commercialize the Galleri test in South Korea, with subject to final execution of definitive agreements, a possible extension into other Asian geographies, including Japan and Singapore. SCT will perform key activities to drive adoption of Galleri. Initially, tests will be performed in GRAIL’s clinical laboratory in Research Triangle Park, North Carolina.
The strategic investment is subject to execution of the definitive collaboration agreements between the parties, as well as customary closing conditions and regulatory approvals. The investment is expected to close in early 2026.
Executive Statement
According to Jaywoo Kim, Executive Vice President of Life Science Business at Samsung C&T, guided by its commitment to advancing next-generation bio-technologies and improving quality of life, Samsung C&T has continuously invested in innovative companies. The collaboration with GRAIL represents a significant new step, moving beyond investment to a strategic business partnership that provides Samsung with a strong foothold for expanding into the cancer screening field and delivering one of these promising technologies to customers in South Korea and across Asia.
According to Sir Harpal Kumar, President, International Business & Biopharma, at GRAIL, they look forward to partnering with Samsung to bring multi-cancer early detection to Asia, beginning in South Korea. Samsung’s significant equity investment strengthens their balance sheet and provides further cash runway as they advance through key milestones to secure reimbursement for Galleri in the U.S. and key international markets.
